[Pharmacology of calcium antagonists].
The present increase in indications for application of calcium antagonists--beyond the area of coronary heart disease--is confirmed by pharmacological analyses. Due to calcium antagonists the contractility is decreased, which is followed by a decreased oxygen consumption in the heart and a relaxation of the vessels. Nowadays, the anti-arrhythmic and cardio-protective effects as well as the prevention of coronary spasms by these substances can be pharmacologically established.
D000787:Angina Pectoris / Q000188:drug therapy; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001161:Arteriosclerosis / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D003326:Coronary Circulation / Q000187:drug effects; D003327:Coronary Disease / Q000188:drug therapy; D003329:Coronary Vasospasm / Q000188:drug therapy; D006329:Heart Conduction System / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D009200:Myocardial Contraction / Q000187:drug effects; D009203:Myocardial Infarction / Q000517:prevention & control; D011817:Rabbits
D002121:Calcium Channel Blockers
Pharmakologie der Kalzium-Antagonisten.